Table 1.
Patient Characteristics Overall and by pCR
| Overall | pCR | |||||
|---|---|---|---|---|---|---|
| No | Yes | p-value | ||||
| N | N | % | N | % | ||
| 142 | 70 | 72 | ||||
| Race | ||||||
| Black | 23 | 11 | 15.7% | 12 | 16.7% | |
| Spanish/Hispanic | 29 | 15 | 21.4% | 14 | 19.4% | |
| White | 84 | 43 | 61.4% | 41 | 56.9% | |
| Asian/Pacific Islander | 6 | 1 | 1.4% | 5 | 6.9% | 0.480 |
| Age at diagnosis, years | ||||||
| Median (range) | 50 (21–81) | 48 | (25–74) | 52 | (21–81) | 0.0954 |
| Histology | ||||||
| Ductal | 133 | 64 | 91.4% | 69 | 95.8% | |
| Other | 9 | 6 | 8.6% | 3 | 4.2% | <0.0001 |
| Clinical T stage | ||||||
| T1 | 23 | 7 | 10.0% | 16 | 20.8% | |
| T2 | 71 | 34 | 48.6% | 37 | 51.4% | |
| T3 | 23 | 15 | 21.4% | 8 | 11.1% | |
| T4 | 25 | 14 | 20.0% | 11 | 15.3% | 0.138 |
| Clinical N stage | ||||||
| N0 | 45 | 20 | 28.6% | 25 | 34.7% | |
| N1 | 60 | 32 | 45.7% | 28 | 38.9% | |
| N2 | 4 | 1 | 1.4% | 3 | 4.2% | |
| N3 | 33 | 17 | 24.3% | 16 | 22.2% | 0.633 |
| Clinical stage | ||||||
| I | 5 | 1 | 1.4% | 4 | 5.6% | |
| II | 75 | 38 | 54.3% | 37 | 51.4% | |
| III | 62 | 31 | 44.3% | 31 | 43.0% | 0.513 |
| Nuclear grade | ||||||
| II | 33 | 20 | 28.6% | 13 | 18.1% | |
| III | 106 | 49 | 70.0% | 57 | 79.2% | |
| Not reported | 3 | 1 | 1.4% | 2 | 2.8% | 0.214 |
| LVI | ||||||
| Positive | 28 | 21 | 30.0% | 7 | 9.7% | |
| Negative | 114 | 49 | 70.0% | 65 | 90.3% | 0.005 |
| ER | ||||||
| Positive | 68 | 40 | 57.1% | 28 | 38.9% | |
| Negative | 74 | 30 | 42.9% | 44 | 61.1% | 0.045 |
| PR | ||||||
| Positive | 50 | 31 | 44.3% | 19 | 26.4% | |
| Negative | 91 | 39 | 55.7% | 52 | 72.2% | |
| Not reported | 1 | 0 | 1 | 1.4% | 0.046 | |
Abbreviations: pCR, pathologic complete response; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor.
*
other includes lobular (n=3) and mixed ductal/lobular (n=6) histology